Published in Clin Diagn Lab Immunol on July 01, 2003
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol (2007) 0.97
Heterogeneity in lipopolysaccharide responsiveness of endothelial cells identified by gene expression profiling: role of transcription factors. Clin Exp Immunol (2006) 0.95
CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res (2011) 0.94
Lipopolysaccharide appears to activate human endometrial endothelial cells through TLR-4-dependent and TLR-4-independent mechanisms. Am J Reprod Immunol (2012) 0.86
The role of endothelial interleukin-8/NADPH oxidase 1 axis in sepsis. Immunology (2010) 0.83
Effects of sevoflurane postconditioning on cell death, inflammation and TLR expression in human endothelial cells exposed to LPS. J Transl Med (2013) 0.81
Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (1998) 37.15
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med (1992) 20.79
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med (1999) 9.23
TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet (2000) 8.79
Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem (1999) 7.81
Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4) J Exp Med (1999) 7.62
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling. Nature (1998) 6.49
Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis (1990) 3.20
The Toll-receptor family and control of innate immunity. Curr Opin Immunol (1999) 3.08
Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem (2000) 3.06
Critical roles of Toll-like receptors in host defense. Crit Rev Immunol (2000) 1.63
Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature (1997) 1.60
Micrococci and peptidoglycan activate TLR2-->MyD88-->IRAK-->TRAF-->NIK-->IKK-->NF-kappaB signal transduction pathway that induces transcription of interleukin-8. Infect Immun (2001) 1.59
Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. J Immunol (1999) 1.51
Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood (2000) 1.48
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol (1999) 1.46
Neutropenia, fever, and infection. Am J Med (1984) 1.42
An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. Infection (1998) 1.07
Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. Clin Infect Dis (1999) 0.96
Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. J Infect Dis (1992) 0.93
Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis (2001) 0.92
Cytokine production by peripheral blood monocytes and T cells during haemopoietic recovery after intensive chemotherapy. Br J Haematol (1993) 0.90
Serum concentrations of E-selectin, P-selectin, ICAM-1 and interleukin 6 in acute leukaemia patients with chemotherapy-induced leucopenia and bacterial infections. Br J Haematol (1995) 0.89
Serum interleukin-8 (IL-8) and IL-6 concentrations in patients with hematologic malignancies. Blood (1996) 0.84
Regulation of the production of pro-inflammatory cytokines and antagonists during chemotherapy-induced neutropenia in patients with haematological malignancies. Cytokine (1997) 0.83
Interleukin 8 in serum in granulocytopenic patients with infections. Br J Haematol (1994) 0.83
Intrinsic capacity of monocytes to produce cytokines ex vivo in patients with acute lymphoblastic leukaemia. Cytokine (2000) 0.82
TNF alpha, IL-1 beta and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection (1995) 0.80
Serum concentrations of tumour necrosis factor-alpha during chemotherapy-induced leukopenia in patients with acute leukaemia and bacterial infections. Leuk Res (1994) 0.78
Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy. Br J Haematol (1994) 0.78
Serum cytokine levels in patients with neutropenia. Arch Pathol Lab Med (1994) 0.77
Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet (1998) 3.91
The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia (1994) 2.26
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet (2005) 2.03
The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother (1993) 1.77
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol (2003) 1.67
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol (2004) 1.65
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood (2000) 1.47
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol (1999) 1.46
Vincristine revisited. Crit Rev Oncol Hematol (1999) 1.46
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant (2000) 1.42
CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia (1998) 1.39
[A cavernous haemangioma of the colon as the cause of rectal bleeding in childhood]. Ned Tijdschr Geneeskd (2004) 1.39
Successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with refractory anaemia. Br J Haematol (1993) 1.38
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd (2005) 1.38
[Hematopoietic growth factors as supportive treatment in drug-induced agranulocytosis]. Ned Tijdschr Geneeskd (1993) 1.38
Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett (2001) 1.36
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia (2007) 1.36
A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study. Br J Obstet Gynaecol (1986) 1.31
Psychological adaptation and social support of parents of pediatric cancer patients: a prospective longitudinal study. J Pediatr Psychol (2001) 1.28
Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia (2001) 1.28
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood (1988) 1.26
Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer (2006) 1.24
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia (2001) 1.23
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Causes of death--other than progressive leukemia--in childhood acute lymphoblastic (ALL) and myeloid leukemia (AML): the Dutch Childhood Oncology Group experience. Leukemia (2005) 1.19
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis (1999) 1.16
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol (1999) 1.16
High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol (1996) 1.16
IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. J Immunol (1996) 1.16
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia (2002) 1.16
Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother Pharmacol (1999) 1.14
Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatr (2001) 1.14
Therapeutic options in systemic AL amyloidosis. Neth J Med (2004) 1.12
Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Br J Haematol (1999) 1.11
Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol (1983) 1.09
Cytologic "differentiation" in childhood rhabdomyosarcomas following polychemotherapy. Hum Pathol (1984) 1.07
c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). Cytokine (2001) 1.07
A lack of neuroblastoma in Down syndrome: a study from 11 European countries. Cancer Res (1998) 1.07
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest (1988) 1.05
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood (1982) 1.04
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cdelta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J Biol Chem (2001) 1.04
The effect of chemotherapy on the growing skeleton. Cancer Treat Rev (2000) 1.03
MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene (2001) 1.03
Microenvironmental studies of pre-B and B cell development in human and mouse fetuses. J Immunol (1982) 1.03
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet (1991) 1.02
Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia (2004) 1.02
Quality of life in bone tumor patients comparing limb salvage and amputation of the lower extremity. J Surg Oncol (1992) 1.02
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res (1998) 1.02
Hemopoiesis in human fetal and embryonic liver. Microsc Res Tech (1997) 1.02
Magnetic resonance imaging of the brain and neuropsychological evaluation in children treated for acute lymphoblastic leukemia at a young age. Am J Pediatr Hematol Oncol (1993) 1.01
Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. Leukemia (1996) 1.01
The presence of cytokines in Langerhans' cell histiocytosis. J Pathol (1996) 1.01
Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood (1987) 1.01
The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol (2000) 0.99
Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J (2000) 0.99
Low-dose daunorubicin in induction treatment of childhood acute lymphoblastic leukemia: no long-term cardiac damage in a randomized study of the Dutch Childhood Leukemia Study Group. Med Pediatr Oncol (2000) 0.98
Risk factors for psychological maladjustment of parents of children with cancer. J Am Acad Child Adolesc Psychiatry (1999) 0.98
Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes. Mol Cell Biol (1998) 0.98
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood (1987) 0.98
Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity? Support Care Cancer (2008) 0.97
Brief report: an intervention program for parents of pediatric cancer patients: a randomized controlled trial. J Pediatr Psychol (1998) 0.96
Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species? Int J Oncol (2002) 0.96
MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia (2012) 0.96
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med (1999) 0.95
A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol (1996) 0.95
Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol (2001) 0.95
Health-related quality of life and adverse late effects in adult (very) long-term childhood cancer survivors. Eur J Cancer (2006) 0.95
Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol (2000) 0.95
Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia (2011) 0.95
Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia (2011) 0.95
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res (1991) 0.95
Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by gamma-glutamyltranspeptidase. Int Immunol (2001) 0.94
A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation. Leukemia (1999) 0.94
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia (2001) 0.94
Regulation of p100 (NFKB2) expression in human monocytes in response to inflammatory mediators and lymphokines. Leukemia (1998) 0.93
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res (2013) 0.93
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol (1999) 0.93
Changes in body composition after childhood cancer treatment: impact on future health status--a review. Crit Rev Oncol Hematol (2007) 0.92
RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet (2003) 0.92
Late effects in adult survivors of childhood cancer: the need for life-long follow-up. Ann Oncol (2007) 0.92
Homozygous alpha 2-antiplasmin deficiency. Lancet (1979) 0.92
Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. Blood (1993) 0.92
Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. J Allergy Clin Immunol (1998) 0.91
Langerhans' cell histiocytosis: expression of leukocyte cellular adhesion molecules suggests abnormal homing and differentiation. Am J Pathol (1994) 0.91
Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia (1999) 0.91
Megaprostheses in the treatment of primary malignant and metastatic tumors in the hip region. J Surg Oncol (1989) 0.90